N-(3,4-DIMETHOXYPHENETHYL)-3-(4-(3-ISOPROPYL-1-METHYL-1H-INDOL-2-YLSULFONYL)PHENOXY)-N-METHYLPROPAN-2-AMINE
| 中文名稱 | N-(3,4-DIMETHOXYPHENETHYL)-3-(4-(3-ISOPROPYL-1-METHYL-1H-INDOL-2-YLSULFONYL)PHENOXY)-N-METHYLPROPAN-2-AMINE |
|---|---|
| 中文同義詞 | N-(3,4-DIMETHOXYPHENETHYL)-3-(4-(3-ISOPROPYL-1-METHYL-1H-INDOL-2-YLSULFONYL)PHENOXY)-N-METHYLPROPAN-2-AMINE |
| 英文名稱 | 3,4-DIMETHOXY-N-METHYL-N-[3-[4-[[1-METHYL-3-(1-METHYLETHYL)-1H-INDOL-2-YL]SULFONYL]PHENOXY]PROPYL]BENZENEETHANAMINE OXALATE |
| 英文同義詞 | 3,4-DIMETHOXY-N-METHYL-N-[3-[4-[[1-METHYL-3-(1-METHYLETHYL)-1H-INDOL-2-YL]SULFONYL]PHENOXY]PROPYL]BENZENEETHANAMINE OXALATE;SR 33805 OXALATE;3,4-Dimethoxy-N-methyl-N-(3-(4-((1-methyl-3-(1-methylethyl)-1H-indol-2-yl)sulfonyl)phenoxy)propyl)benzeneethanamineoxal];3,4-Dimethoxy-N-methyl-N-[3-[4-[[1-methyl-3-(1-methylethyl)-1H-indol-2-yl]sulfonyl]phenoxy]propyl]benzeneethanamine;N-(3,4-dimethoxyphenethyl)-3-(4-(3-isopropyl-1-methyl-1H-indol-2-ylsulfonyl)phenoxy)-N-methylpropan-1-amine;N-(3,4-Dimethoxyphenethyl)-3-(4-((3-isopropyl-1-methyl-1H-indol-2-yl)sulfonyl)phenoxy)-N-methylpr;N-(3,4-Dimethoxyphenethyl)-3-(4-((3-isopropyl-1-methyl-1H-indol-2-yl)sulfonyl)phenoxy)-N-methy;N-(3,4-Dimethoxyphenethyl)-3-(4-((3-isopropyl-1-methyl-1H-indol-2-yl)sulfonyl)phenoxy)-N-methylpropan-1-amine oxalate |
| CAS號 | 121346-32-5 |
| 分子式 | C32H40N2O5S |
| 分子量 | 564.74 |
| EINECS號 | |
| 相關(guān)類別 | Calcium channel |
| Mol文件 | 121346-32-5.mol |
| 結(jié)構(gòu)式 |  |
N-(3,4-DIMETHOXYPHENETHYL)-3-(4-(3-ISOPROPYL-1-METHYL-1H-INDOL-2-YLSULFONYL)PHENOXY)-N-METHYLPROPAN-2-AMINE 性質(zhì)
| 沸點 | 724.1±60.0 °C(Predicted) |
|---|---|
| 密度 | 1.15±0.1 g/cm3(Predicted) |
| 儲存條件 | Store at RT |
| 酸度系數(shù)(pKa) | 8.82±0.50(Predicted) |
N-(3,4-DIMETHOXYPHENETHYL)-3-(4-(3-ISOPROPYL-1-METHYL-1H-INDOL-2-YLSULFONYL)PHENOXY)-N-METHYLPROPAN-2-AMINE 用途與合成方法
SR 33805 (analog) 是一種具有口服活性的 Ca2+通道阻滯劑，可靶向抑制平滑肌細胞的增殖。SR 33805 (analog) 通過阻斷鈣通道減少鈣攝取，來抑制血清、血小板源性生長因子和堿性成纖維細胞生長因子誘導(dǎo)的平滑肌細胞增生。SR 33805 (analog) 可在兔體內(nèi)顯著減少內(nèi)皮損傷后動脈內(nèi)膜增厚。SR 33805 (analog) 有望用于心血管疾病研究，如早期動脈粥樣硬化。